Automating Mass Spectrometry Analysis To Accelerate Oligonucleotide Drug Development

By Ada Yee, Scientific Communications

This content is brought to you by Genedata, a Danaher Operating Company.

Oligonucleotide therapeutics are reshaping modern drug development by enabling precise, gene-level interventions that extend far beyond the reach of traditional small-molecule drugs. As approvals steadily rise, so does the demand for reliable analytical approaches that can keep pace with increasingly complex molecules and highly diverse metabolite profiles. Mass spectrometry remains essential for understanding these therapies, yet challenges in sample preparation, data complexity, and metabolite identification can slow development timelines and strain productivity. Automated data-processing capabilities now offer a path forward, reducing manual effort, improving consistency, and accelerating the journey from raw data to meaningful insight.

Discover how leading organizations are modernizing their workflows and advancing oligonucleotide research with purpose-built, automated MS analysis tools.